Catapult’s Network established to identify opportunities for regulation to support innovation within advanced therapies
London, United Kingdom, [Monday 10th February 2025]: A new network will foster collaboration among regulators, industry, and researchers to ensure there is a world-leading regulatory environment in the UK for advanced therapies that supports companies in the development, trial, and launch of these innovative treatments. Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of the cell and gene therapy industry, and the Birmingham Health Partners Centre for Regulatory Science and Innovation (CRSI) established the network with funding from Innovate UK and support from the MHRA.
Published on the 10th of february 2025. Read the full news report here.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (20 mai 2025). Catapult’s Network established to identify opportunities for regulation to support innovation within advanced therapies. ELSIBI. Consulté le 18 février 2026 à l’adresse https://doi.org/10.58079/13yf5





